Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
AssigneeMUSC Foundation for Research Development
InventorCarol Feghali-Bostwick
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treatment or prevention of tumor growth, fibrosis, acute lung injury or a combination thereof. In one embodiment, the composition comprises a peptide derived from the C-terminal region of endostatin.
Claims18
A method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a composition comprising:
- a) a C-terminal endostatin-derived peptide that is:
- i) 9 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 1,
- ii) 36 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 2, or
- iii) 48 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 3;
- or
- b) a nucleic acid molecule encoding a C-terminal endostatin-derived peptide that is:
- i) 9 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 1,
- ii) 36 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 2, or
- iii) 48 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 3.
A method of treating a fibrotic or fibrotic-related disease or disorder in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a composition comprising:
- a) a C-terminal endostatin-derived peptide that is:
- i) 36 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 2, or
- ii) 24 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 4;
- or
- b) a nucleic acid molecule encoding a C-terminal endostatin-derived peptide that is:
- i) 36 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 2 or
- ii) 24 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 4.
A method of treating a disease or disorder in a subject in need thereof, wherein the disease or disorder is a fibrotic or fibrotic-related disease or disorder or acute lung injury, wherein the method comprises administering to the subject an effective amount of a composition comprising:
- a) a C-terminal endostatin-derived peptide that is 36 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 2;
- or
- b) a nucleic acid molecule encoding a C-terminal endostatin-derived peptide that is 36 amino acids in length and has the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.